Browse Items (2 total)

Tags: Streptococcus pneumoniae/*drug effects

Sort by:

Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.

The efficacy of a new pharmacokinetically enhanced formulation of amoxycillin/clavulanate (AMX/CA) 2000/125 mg, twice daily, designed to provide adequate levels of amoxycillin over the 12-h dosing interval to eradicate penicillin-resistant…

Tags: *Treatment Outcome, 2002, 80 and over, Adolescent, Adult, Aged, Amoxicillin-Potassium Clavulanate Combination/administration & dosage/*pharmacokinetics/pharmacology/*therapeutic use, Amoxicillin/adverse effects/therapeutic use, Bacterial, Bacterial/drug therapy/immunology, Bronchitis/drug therapy/microbiology, Combination/adverse effects/*therapeutic use, Department of Internal Medicine, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Female, File Thomas M Jr, Follow-Up Studies, Humans, International journal of antimicrobial agents, Jacobs Michael R, Male, Microbial Sensitivity Tests, Middle Aged, Multicenter Studies as Topic, NEOMED College of Medicine, Pneumonia, Poole Michael D, Respiratory Tract Infections/*drug therapy/metabolism/microbiology, Streptococcal Infections/*drug therapy/metabolism/microbiology, Streptococcus pneumoniae/*drug effects, Wynne Brian

A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.

Patients with chronic obstructive pulmonary disease (COPD) may progress to community-acquired pneumonia (CAP), but there has been no formal study of the factors responsible. We studied the influence of severity of underlying lung disease, pathogen…

Tags: *Anti-Bacterial Agents/pharmacokinetics/therapeutic use, *Community-Acquired Infections/drug therapy/microbiology/physiopathology/prevention & control, *Models, *Pneumonia, 2009, Adelman Martin H, Aged, Area Under Curve, Bacterial/drug therapy/microbiology/physiopathology/prevention & control, Biological, Bronchitis, Chronic Obstructive/drug therapy/microbiology/*physiopathology, Chronic/drug therapy/microbiology/physiopathology, Department of Internal Medicine, Disease Progression, Female, File Thomas M Jr, Humans, International journal of antimicrobial agents, Klugman Keith P, Lavin Bruce, Lung Diseases/complications/drug therapy/microbiology, Lung/microbiology, Male, Microbial Sensitivity Tests, Middle Aged, Monte Scott V, NEOMED College of Medicine, Paladino Joseph A, Pneumococcal/drug therapy/microbiology/physiopathology/prevention & control, Pneumonia, Pulmonary Disease, Schentag Jerome J, Severity of Illness Index, Singer Mendel E, Streptococcus pneumoniae/*drug effects, Yu Victor L

Output Formats

atom, dcmes-xml, json, omeka-xml, rss2